Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will participate in a prerecorded fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The chat will be available on January 10, 2022, at 7:00 am ET on Milestone's website. Milestone focuses on innovative cardiovascular medicines, with its lead product, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 trials for atrial fibrillation.

MONTREAL and CHARLOTTE, N.C., Jan. 4, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference being held on January 10-13, 2022.

The prerecorded fireside chat will become available on Monday, January 10, 2022 at 7:00am ET and can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the fireside chat will be available on the same website 90 days following the presentation.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma.

Contact

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301452873.html

SOURCE Milestone Pharmaceuticals, Inc.

FAQ

When will Milestone Pharmaceuticals present at the H.C. Wainwright BIOCONNECT Virtual Conference?

Milestone Pharmaceuticals will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022.

What is Milestone Pharmaceuticals' focus in the biopharmaceutical sector?

Milestone Pharmaceuticals focuses on the development and commercialization of innovative cardiovascular medicines.

What is the lead product candidate of Milestone Pharmaceuticals?

Milestone's lead product candidate is etripamil, currently in clinical trials for treating paroxysmal supraventricular tachycardia and atrial fibrillation.

Where can I access the fireside chat from Milestone Pharmaceuticals?

The fireside chat will be accessible on Milestone's website starting January 10, 2022, at 7:00 am ET.

How long will the replay of the fireside chat be available?

The archived replay of the fireside chat will be available for 90 days following the presentation.